Factors affecting bone age maturation during 3 years of growth hormone treatment in patients with idiopathic growth hormone deficiency and idiopathic short stature: Analysis of data from the LG growth study.

The IGF-1 SDS increased prominently during the first year of GH treatment ( P = .003 compared to baseline IGF-1 SDS), but the IGF-1 SDS then exhibited a decreasing trend (Fig. 2 B). 3.3 Factors associated with BA progression during GH treatment in iGHD subjects BA progression greater than 3 years during GH treatment was found in 82.1% (64/78) of the subjects with iGHD.

also in 47,180 other papers